278 related articles for article (PubMed ID: 30693974)
1. Transglutaminase 2 takes center stage as a cancer cell survival factor and therapy target.
Eckert RL
Mol Carcinog; 2019 Jun; 58(6):837-853. PubMed ID: 30693974
[TBL] [Abstract][Full Text] [Related]
2. Transamidase site-targeted agents alter the conformation of the transglutaminase cancer stem cell survival protein to reduce GTP binding activity and cancer stem cell survival.
Kerr C; Szmacinski H; Fisher ML; Nance B; Lakowicz JR; Akbar A; Keillor JW; Lok Wong T; Godoy-Ruiz R; Toth EA; Weber DJ; Eckert RL
Oncogene; 2017 May; 36(21):2981-2990. PubMed ID: 27941875
[TBL] [Abstract][Full Text] [Related]
3. Type II transglutaminase stimulates epidermal cancer stem cell epithelial-mesenchymal transition.
Fisher ML; Adhikary G; Xu W; Kerr C; Keillor JW; Eckert RL
Oncotarget; 2015 Aug; 6(24):20525-39. PubMed ID: 25971211
[TBL] [Abstract][Full Text] [Related]
4. Transglutaminase is a tumor cell and cancer stem cell survival factor.
Eckert RL; Fisher ML; Grun D; Adhikary G; Xu W; Kerr C
Mol Carcinog; 2015 Oct; 54(10):947-58. PubMed ID: 26258961
[TBL] [Abstract][Full Text] [Related]
5. Role of Tissue Transglutaminase Catalytic and Guanosine Triphosphate-Binding Domains in Renal Cell Carcinoma Progression.
Ulukan B; Bihorac A; Sipahioglu T; Kiraly R; Fesus L; Telci D
ACS Omega; 2020 Nov; 5(43):28273-28284. PubMed ID: 33163811
[TBL] [Abstract][Full Text] [Related]
6. Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival.
Fisher ML; Keillor JW; Xu W; Eckert RL; Kerr C
Mol Cancer Res; 2015 Jul; 13(7):1083-94. PubMed ID: 25934691
[TBL] [Abstract][Full Text] [Related]
7. Transglutaminase-2: evolution from pedestrian protein to a promising therapeutic target.
Agnihotri N; Mehta K
Amino Acids; 2017 Mar; 49(3):425-439. PubMed ID: 27562794
[TBL] [Abstract][Full Text] [Related]
8. Transglutaminase is a mesothelioma cancer stem cell survival protein that is required for tumor formation.
Adhikary G; Grun D; Alexander HR; Friedberg JS; Xu W; Keillor JW; Kandasamy S; Eckert RL
Oncotarget; 2018 Oct; 9(77):34495-34505. PubMed ID: 30349644
[TBL] [Abstract][Full Text] [Related]
9. Sulforaphane covalently interacts with the transglutaminase 2 cancer maintenance protein to alter its structure and suppress its activity.
Rorke EA; Adhikary G; Szmacinski H; Lakowicz JR; Weber DJ; Godoy-Ruiz R; Puranik P; Keillor JW; Gates EWJ; Eckert RL
Mol Carcinog; 2022 Jan; 61(1):19-32. PubMed ID: 34610184
[TBL] [Abstract][Full Text] [Related]
10. Transglutaminase 2: a multi-tasking protein in the complex circuitry of inflammation and cancer.
Mehta K; Kumar A; Kim HI
Biochem Pharmacol; 2010 Dec; 80(12):1921-9. PubMed ID: 20599779
[TBL] [Abstract][Full Text] [Related]
11. The GTP binding activity of transglutaminase 2 promotes bone metastasis of breast cancer cells by downregulating microRNA-205.
Seo S; Moon Y; Choi J; Yoon S; Jung KH; Cheon J; Kim W; Kim D; Lee CH; Kim SW; Park KS; Lee DH
Am J Cancer Res; 2019; 9(3):597-607. PubMed ID: 30949413
[TBL] [Abstract][Full Text] [Related]
12. Transglutaminase 2: The Maestro of the Oncogenic Mediators in Renal Cell Carcinoma.
Nezir AE; Ulukan B; Telci D
Med Sci (Basel); 2019 Feb; 7(2):. PubMed ID: 30736384
[TBL] [Abstract][Full Text] [Related]
13. Competitive Binding of Magnesium to Calcium Binding Sites Reciprocally Regulates Transamidase and GTP Hydrolysis Activity of Transglutaminase 2.
Jeong EM; Lee KB; Kim GE; Kim CM; Lee JH; Kim HJ; Shin JW; Kwon MA; Park HH; Kim IG
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31991788
[TBL] [Abstract][Full Text] [Related]
14. Transglutaminase 2 Binds to the CD44v6 Cytoplasmic Domain to Stimulate CD44v6/ERK1/2 Signaling and Maintain an Aggressive Cancer Phenotype.
Chen X; Adhikary G; Newland JJ; Xu W; Keillor JW; Weber DJ; Eckert RL
Mol Cancer Res; 2023 Sep; 21(9):922-932. PubMed ID: 37227250
[TBL] [Abstract][Full Text] [Related]
15. Transglutaminase 2 maintains a colorectal cancer stem phenotype by regulating epithelial-mesenchymal transition.
Ayinde O; Wang Z; Pinton G; Moro L; Griffin M
Oncotarget; 2019 Jul; 10(44):4556-4569. PubMed ID: 31360304
[TBL] [Abstract][Full Text] [Related]
16. Transglutaminase 2 Prevents Premature Senescence and Promotes Osteoblastic Differentiation of Mesenchymal Stem Cells through NRF2 Activation.
Lee SJ; Shin JW; Kwon MA; Lee KB; Kim HJ; Lee JH; Kang HS; Jun JK; Cho SY; Kim IG
Stem Cells Int; 2023; 2023():8815888. PubMed ID: 37900967
[TBL] [Abstract][Full Text] [Related]
17. Tissue transglutaminase expression is necessary for adhesion, metastatic potential and cancer stemness of renal cell carcinoma.
Bagatur Y; Ilter Akulke AZ; Bihorac A; Erdem M; Telci D
Cell Adh Migr; 2018 Mar; 12(2):138-151. PubMed ID: 28498731
[TBL] [Abstract][Full Text] [Related]
18. Tissue transglutaminase induces Epithelial-Mesenchymal-Transition and the acquisition of stem cell like characteristics in colorectal cancer cells.
Ayinde O; Wang Z; Griffin M
Oncotarget; 2017 Mar; 8(12):20025-20041. PubMed ID: 28223538
[TBL] [Abstract][Full Text] [Related]
19. Tissue transglutaminase-mediated chemoresistance in cancer cells.
Verma A; Mehta K
Drug Resist Updat; 2007; 10(4-5):144-51. PubMed ID: 17662645
[TBL] [Abstract][Full Text] [Related]
20. Tissue transglutaminase promotes or suppresses tumors depending on cell context.
Chhabra A; Verma A; Mehta K
Anticancer Res; 2009 Jun; 29(6):1909-19. PubMed ID: 19528447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
